Results From the Immunis Phase 2 Trial of a Stem Cell Secretome Therapy

Why It Matters

By delivering the therapeutic signals of stem cells without live cells, secretome therapy could simplify manufacturing, lower costs, and broaden access to regenerative treatments for the aging population.

Key Takeaways

• IMM01-STEM boosted gait speed 26% vs placebo.
• Trial involved 47 obese seniors with sarcopenia.
• Secretome therapy is cell‑free, simplifying storage and transport.
• Preclinical data showed lean mass gain and fat loss.
• Potential new class of biologics for metabolic aging.

Pulse Analysis

Immunis' approach builds on the growing recognition that the therapeutic value of stem‑cell transplants resides largely in the bioactive factors they release. By isolating the soluble secretome—an ensemble of cytokines, growth factors, and metabolites—the company sidesteps the need for live cells, reducing immunogenic risk and simplifying cold‑chain logistics. Unlike extracellular‑vesicle platforms, which require ultracentrifugation and stringent particle‑size controls, a cell‑free secretome can be lyophilized and shipped in standard containers. This manufacturing shift promises lower cost of goods and a clearer regulatory pathway for biologics that act through multi‑target signaling.

The interim Phase 2 STEM‑META study enrolled 47 obese seniors with age‑related muscle loss, a cohort that typically experiences rapid functional decline. Participants receiving IMM01‑STEM showed a 26 % increase in gait speed relative to placebo—a metric strongly linked to mortality and hospitalization risk in geriatric populations. Secondary observations echoed preclinical findings, including modest gains in lean body mass and reductions in adiposity. While the sample size remains modest, the double‑blind, placebo‑controlled design lends credibility, suggesting that secretome‑driven modulation of inflammation and muscle regeneration can translate into measurable functional benefits.

If confirmed in larger Phase 3 trials, IMM01‑STEM could inaugurate a new class of cell‑free biologics targeting sarcopenia and metabolic syndrome, markets projected to exceed $10 billion as the global population ages. Investors are likely to view Immunis as a pioneer in a space that blends regenerative medicine with scalable biomanufacturing, potentially attracting partnership interest from large pharma seeking to diversify their aging‑care pipelines. Challenges remain, including standardizing secretome composition and demonstrating long‑term safety. Nonetheless, the Phase 2 data positions secretome therapy as a compelling alternative to both traditional stem‑cell grafts and single‑target drugs.